Eligibility for Anti-Amyloid Treatment
Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment. Read the related article in Neurology. Visit NPUb.org/Podcast for associated article links.
▶︎
Blood Biomarkers and Disease-Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s
▶︎
June 2026 Recall: Topics on Parkinsonian Disorders
▶︎
Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
▶︎
July 2026 Recall: Updates in Epilepsy
▶︎
'Miracle' drug giving hope to Alzheimer's sufferers | 60 Minutes Australia
▶︎
E124 | Inside the Fourth Court of Appeals’ Clerk’s Office | Michael Cruz
▶︎
Expert Roundtable on the Use of Anti-Amyloid Therapies for the Treatment of Alzheimer's Disease
▶︎
AH110 - Inside the 2026 U.S. Medicine Use Trends Report with Michael Kleinrock
▶︎
Diagnosis and Management of Migraine in Ten Steps
▶︎
How Memory Medications Like Donepezil & Memantine Work
▶︎
New Resident Guide to Stroke Alerts - Part 1
▶︎
Understanding ARIA – a recognised side-effect of new Alzheimer’s medications
▶︎
If you are 70-80 years old and can still do the following 8 things, you are a rare gem|Dr William Li
▶︎
Alzheimer's Anti-Amyloid Treatments 101: A Beginner's Guide
▶︎
Widening The Search For New Dementia Treatments | Alzheimer's Research UK
▶︎
Discussion of New CIDP Guidelines
▶︎
Alzheimer’s Disease — Anti-Amyloid Medications, Early Detection, and Screening | NEJM
▶︎
Episode 459: This is NOT Your Father's MS Rehabilitation with 3 Top MS Rehabilitation Experts
▶︎
Unpacking Cisco Live
▶︎